NCT00979615View on ClinicalTrials.gov

Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

PHASE4CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 30, 2009

Conditions
Vasomotor Rhinitis
Interventions
DRUG

Olopatadine HCL (Patanase) Nasal Spray, 0.6%

2 sprays/ nostril BID

DRUG

Azelastine HCl (Astelin) Nasal Spray, 137 mcg

2 sprays/ nostril BID

Trial Locations (1)

76134

Contact Alcon Call Center For Trial Locations, Fort Worth

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT00979615 - Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis | Biotech Hunter | Biotech Hunter